This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-09-0064v1 69/18/7357    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Kadota, M. Articles by Lee, M. P. PubMed PubMed Citation Articles by Kadota, M. Articles by Lee, M. P.

Identification of Novel Gene Amplifications in Breast Cancer and Coexistence of Gene Amplification with an Activating Mutation of PIK3CA

¹ Laboratory of Population Genetics, Center for Cancer Research, ² Laboratory of Cancer Biology and Genetics, Center for Cancer Research, and ³ Basic Prevention Science Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland and ⁴ Laboratory of Pathology, Toyama University Hospital; ⁵ Department of Surgery, University of Toyama, Toyama, Japan

Requests for reprints: Maxwell P. Lee, Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, Building 41, Room D702, 41 Library Drive, Bethesda, MD 20892. Phone: 301-435-8956; Fax: 301-435-8963; E-mail: leemax{at}mail.nih.gov.

Key Words: DNA copy number • gene amplification • oncogene • somatic mutation • breast cancer

To identify genetic events that characterize cancer progression, we conducted a comprehensive genetic evaluation of 161 primary breast tumors. Similar to the "mountain-and-hill" view of mutations, gene amplification also shows high- and low-frequency alterations in breast cancers. The frequently amplified genes include the well-known oncogenes ERBB2, FGFR1, MYC, CCND1, and PIK3CA, whereas other known oncogenes that are amplified, although less frequently, include CCND2, EGFR, FGFR2, and NOTCH3. More importantly, by honing in on minimally amplified regions containing three or fewer genes, we identified six new amplified genes: POLD3, IRAK4, IRX2, TBL1XR1, ASPH, and BRD4. We found that both the IRX2 and TBL1XR1 proteins showed higher expression in the malignant cell lines MCF10CA1h and MCF10CA1a than in their precursor, MCF10A, a normal immortalized mammary epithelial cell line. To study oncogenic roles of TBL1XR1, we performed knockdown experiments using a short hairpin RNA approach and found that depletion of TBL1XR1 in MCF10CA1h cells resulted in reduction of cell migration and invasion as well as suppression of tumorigenesis in mouse xenografts. Intriguingly, our mutation analysis showed the presence of activation mutations in the PIK3CA gene in a subset of tumors that also had DNA copy number increases in the PIK3CA locus, suggesting an additive effect of coexisting activating amino acid substitution and dosage increase from amplification. Our gene amplification and somatic mutation analysis of breast primary tumors provides a coherent picture of genetic events, both corroborating and novel, offering insight into the genetic underpinnings of breast cancer progression. [Cancer Res 2009;69(18):7357–65]